Literature DB >> 20920694

Outcomes in patients with rheumatoid arthritis and myocardial infarction.

Mark L Francis1, Joji J Varghese, Jacob M Mathew, Sushma Koneru, Steven L Scaife, Whitney E Zahnd.   

Abstract

BACKGROUND: Patients with rheumatoid arthritis have an increased risk for accelerated atherosclerosis. It is unknown, however, whether rheumatoid arthritis also increases in-hospital mortality after a myocardial infarction or influences the therapy patients receive.
METHODS: A cross-sectional analysis of 1,112,676 patients with myocardial infarction in the 2003-2005 Nationwide Inpatient Sample was performed.
RESULTS: Patients with rheumatoid arthritis were 39% more likely to receive medical therapy (odds ratio [OR], 1.39; 95% confidence interval [CI], 1.30-1.49) than interventional therapy. By using logistic regression, we adjusted for confounding variables to determine the effect of rheumatoid arthritis on the selection of therapy and found that rheumatoid arthritis itself was associated with a 38% increased likelihood of undergoing thrombolysis (OR, 1.38; 95% CI, 1.10-1.71) and a 27% increased likelihood of undergoing percutaneous coronary intervention (OR, 1.27; 95% CI, 1.17-1.39). For the primary outcome measure, we determined that patients with rheumatoid arthritis overall had a 24% better in-hospital mortality compared with other patients with a myocardial infarction (OR, 0.76; 95% CI, 0.68-0.86), which was 34% better after adjusting for confounding variables (OR, 0.66; 95% CI, 0.59-0.74). This better in-hospital mortality was seen in patients with rheumatoid arthritis undergoing medical therapy (adjusted OR, 0.67; 95% CI, 0.59-0.75) and percutaneous coronary intervention (adjusted OR, 0.47; 95% CI, 0.32-0.70), but not in patients undergoing thrombolysis or coronary artery bypass grafting.
CONCLUSIONS: Among patients with myocardial infarction, rheumatoid arthritis was associated with an increased use of thrombolysis and percutaneous coronary intervention. Moreover, patients with rheumatoid arthritis had an in-hospital survival advantage, particularly those undergoing medical therapy and percutaneous coronary intervention.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20920694     DOI: 10.1016/j.amjmed.2010.05.017

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  Atherosclerotic vascular disease in the autoimmune rheumatologic patient.

Authors:  Rekha Mankad
Journal:  Curr Atheroscler Rep       Date:  2015-04       Impact factor: 5.113

Review 2.  Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure.

Authors:  Kerry Wright; Cynthia S Crowson; Sherine E Gabriel
Journal:  Heart Fail Clin       Date:  2014-01-10       Impact factor: 3.179

3.  Longterm outcomes and treatment after myocardial infarction in patients with rheumatoid arthritis.

Authors:  Sara S McCoy; Cynthia S Crowson; Hilal Maradit-Kremers; Terry M Therneau; Veronique L Roger; Eric L Matteson; Sherine E Gabriel
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

4.  Outcomes of acute cardiovascular events in rheumatoid arthritis and systemic lupus erythematosus: a population-based study.

Authors:  Chao-Han Lai; Cheng-Yang Hsieh; April Barnado; Li-Ching Huang; Sheau-Chiann Chen; Liang-Miin Tsai; Yu Shyr; Chung-Yi Li
Journal:  Rheumatology (Oxford)       Date:  2020-06-01       Impact factor: 7.580

5.  Long-term clinical outcomes of patients with rheumatoid arthritis and concomitant coronary artery disease.

Authors:  Marco Spartera; Cosmo Godino; Elena Baldissera; Corrado Campochiaro; Ketty La Spina; Patrizia Aiello; Anna Salerno; Michela Cera; Valeria Magni; Richard J Jabbour; Lorenzo Dagna; Moreno Tresoldi; Alberto Cappelletti; Ottavio Alfieri; Antonio Colombo; Maria Grazia Sabbadini; Alberto Margonato
Journal:  Am J Cardiovasc Dis       Date:  2017-02-15

6.  The impact of inflammatory rheumatic diseases on the presentation, severity, and outcome of acute coronary syndrome.

Authors:  Ilan Ben-Zvi; Ilan Goldenberg; Shlomi Matetzky; Chagai Grossman; Avishay Elis; Natalie Gavrielov-Yusim; Avi Livneh
Journal:  Clin Rheumatol       Date:  2014-06-15       Impact factor: 2.980

Review 7.  Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

Authors:  Deborah P M Symmons; Sherine E Gabriel
Journal:  Nat Rev Rheumatol       Date:  2011-05-31       Impact factor: 20.543

8.  Treatments and in-hospital mortality in acute myocardial infarction patients with rheumatoid arthritis: a nationwide retrospective cohort study in Japan.

Authors:  Toshiaki Isogai; Hiroki Matsui; Hiroyuki Tanaka; Naoto Yokogawa; Kiyohide Fushimi; Hideo Yasunaga
Journal:  Clin Rheumatol       Date:  2017-01-26       Impact factor: 2.980

Review 9.  Rheumatoid arthritis and cardiovascular disease.

Authors:  Cynthia S Crowson; Katherine P Liao; John M Davis; Daniel H Solomon; Eric L Matteson; Keith L Knutson; Mark A Hlatky; Sherine E Gabriel
Journal:  Am Heart J       Date:  2013-08-29       Impact factor: 4.749

10.  Increased 30-day and 1-year mortality rates and lower coronary revascularisation rates following acute myocardial infarction in patients with autoimmune rheumatic disease.

Authors:  Sharon Van Doornum; Megan Bohensky; Mark A Tacey; Caroline A Brand; Vijaya Sundararajan; Ian P Wicks
Journal:  Arthritis Res Ther       Date:  2015-02-27       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.